![]() |
市场调查报告书
商品编码
1494319
北美 ELISA 诊断测试市场预测至 2030 年 - 区域分析 - 按采用情况、测试类型、应用程式和最终用户North America ELISA Diagnostics Tests Market Forecast to 2030 - Regional Analysis - by Adoption, Test Type, Application, and End User |
2022年北美ELISA诊断测试市值为5.5469亿美元,预计到2030年将达到10.0956亿美元;预计2022年至2030年复合年增长率为7.8%。
动物传染病的增加推动北美 ELISA 诊断测试市场
根据美国疾病管制与预防中心 (CDC) 的报告,光是在美国,与动物或环境有关的肠道疾病就导致 45 万例、5,000 例住院病例和 76 例死亡。这些疾病是在人类接触动物粪便或体液时观察到的,透过动物接触传播的病原体可能对人类造成危险。此外,世界动物卫生组织发布的报告显示,60%的人类感染是与动物有关的疾病。报告也提到,75%的新发动物疾病可以传播给人类,每年有五种动物新兴疾病。根据世界卫生组织的报告,全世界每年约有 55,000 起医疗索赔与狂犬病感染有关,其中主要是因被感染的狗咬伤而导致的儿童。此外,《动物健康》报告显示,六种与动物相关的疾病(汉他病毒、淋巴球、脉络膜脑膜炎病毒(LCMV)、鼠疫、沙门氏菌、鼠咬热和兔热病)在12 年内造成了价值800 亿美元的经济损失。在六种疾病中,仅一种与动物相关的疾病「口蹄疫」每年就给全球农民带来高达 210 亿美元的损失。乳牛中存在的持续性淋巴细胞增多症(PL)可能会在怀孕期间感染犊牛。乳牛的产奶量可能会严重下降,并可能感染周围的其他动物。在这种情况下,酶联免疫吸附测定 (ELISA) 测试最适合测试受感染牛的 PL 疾病阳性,因为它可以揭示正确的淋巴细胞计数临床测试结果。此外,根据兽医报告,该测试对于感染 55 天的动物的敏感性为 95%。因此,兽医通常建议对8个月及以上的动物进行ELISA检测。因此,动物相关疾病发生率的上升推动了对 ELISA 检测的需求。
北美 ELISA 诊断测试市场概述
ClinMed 国际图书馆 2017 年报告显示,「肠贾第鞭毛虫」是美国最常见的肠道寄生虫感染。而且,在该国,12岁以上人口中有22.5%感染「弓形虫」。此外,近二十年来,美国人畜共患病发生率不断上升,成为美国人口传染病病例上升的重要原因。此外,CDC 2023报告显示,2022年1月美国禽流感(AI)发生率呈上升趋势。因此,为了控制美国的禽流感感染,提供了商业 ELISA 检测试剂盒来确认任何阳性结果。因此,由于人畜共通传染病病例较多,人类传染病发生率不断上升,推动了 ELISA 诊断测试在美国的采用。
北美 ELISA 诊断测试市场收入及 2030 年预测(百万美元)
北美 ELISA 诊断测试市场细分
北美 ELISA 诊断测试市场根据采用情况、测试类型、应用程式、最终用户和国家/地区进行细分。根据采用情况,北美 ELISA 诊断测试市场分为人类和兽医市场。 2022 年,人类细分市场将占据更大的市场份额。
就测试类型而言,北美ELISA诊断测试市场分为夹心ELISA、间接ELISA、竞争性ELISA以及多重便携式ELISA。 2022 年,间接 ELISA 细分市场占据最大的市场份额。
根据应用,北美 ELISA 诊断测试市场分为自体免疫疾病、传染病、癌症诊断、蛋白质定量等。 2022 年,传染病领域占据最大的市场份额。
按最终用户划分,北美 ELISA 诊断测试市场分为医院和诊断中心、製药和生物技术公司、兽医医院和诊断实验室等。 2022 年,医院和诊断中心细分市场占据最大的市场份额。
根据国家/地区,北美 ELISA 诊断测试市场分为美国、加拿大和墨西哥。 2022 年,美国主导北美 ELISA 诊断测试市场。
Bio-Rad Laboratories Inc.、Idex Laboratories Inc.、F. Hoffmann-La Roche Ltd.、Thermo Fisher Scientific Inc.、Abbott Laboratories、Danaher Corp.、Pictor Ltd.、DiaSorin SpA、Elabscience Biotechnology Inc. 与 Bio-Techne Corp是北美ELISA 诊断测试市场上的一些领先公司。
The North America ELISA diagnostics tests market was valued at US$ 554.69 million in 2022 and is expected to reach US$ 1,009.56 million by 2030; it is estimated to grow at a CAGR of 7.8% from 2022 to 2030.
Rising Infectious Diseases Among Animals Fuel North America ELISA Diagnostics Tests Market
According to the Centers for Disease Control and Prevention (CDC) report, enteric diseases linked to animals or environments account for 450,000 case of illnesses, 5,000 hospitalizations, and 76 deaths among humans in the US alone. These illnesses are observed in humans in contact with animal feces or body fluids, and the pathogens transmitted through animal contact can prove dangerous for humans. Additionally, the World Organization for Animal Health published a report revealing that 60% of human infections comprise animal-related diseases. It also mentioned that 75% of emerging animal diseases can be transmitted to humans, and there are five emerging diseases among animals annually. Every year, about 55,000 healthcare claims are associated with rabies infection worldwide, comprising mainly children due to infected dog bites as per the WHO report. Further, the Health for Animals report reveals that six animal-related diseases (Hantavirus, Lymphocytic, Choriomeningitis virus (LCMV), plague, salmonella, rat bite fever, and tularemia) caused economic losses worth US$ 80 billion within 12 years. Among six, just one animal-related disease, "Foot and Mouth," costs farmers up to US$ 21 billion globally every year. The persistent lymphocytosis (PL) present among cows can infect their calves during pregnancy. Cows can suffer from serious milk production declines and may infect other surrounding animals. In this scenario, Enzyme-Linked Immunosorbent Assay (ELISA) test is best suited to test infected cow's positive for PL disease as it reveals proper lymphocyte count clinical results on testing. Further, the test is reported by veterinarian to be 95% sensitive for animals infected with 55 days of infection. Therefore, ELISA test is commonly recommended by veterinarian for animals aged 8 months and above. Thus, rising incidence of animal-associated diseases propels the demand for ELISA tests.
North America ELISA Diagnostics Tests Market Overview
The ClinMed International Library 2017 report reveals that "Giardia Intestinalis" is the most common intestinal parasitic infection in the US. Moreover, in the country, 22.5% of the population over 12 years of age gets infected with "Toxoplasma Gondii". Further, in the last two decades, there has been a rise in the incidence of zoonotic diseases in the US, becoming a significant cause of rising infectious disease cases among the US population. Additionally, the CDC 2023 report reveals that the incidence of avian influenza (AI) was on the rise in the US in January 2022. It stated that 59,031,321 birds were affected due to AI in the US as per the CDC report. Therefore, to control AI infections in the US, commercial ELISA test kits were made available to confirm any positives. Thus, rising incidences of infectious diseases among humans due to high zoonotic disease cases boost the adoption of ELISA diagnostic tests in the US.
North America ELISA Diagnostics Tests Market Revenue and Forecast to 2030 (US$ Million)
North America ELISA Diagnostics Tests Market Segmentation
The North America ELISA diagnostics tests market is segmented based on adoption, test type, application, end user, and country. Based on adoption, the North America ELISA diagnostics tests market is bifurcated into human and veterinary. The human segment held a larger market share in 2022.
In terms of test type, the North America ELISA diagnostics tests market is segmented into sandwich ELISA, indirect ELISA, competitive ELISA, and multiple & portable ELISA. The indirect ELISA segment held the largest market share in 2022.
Based on application, the North America ELISA diagnostics tests market is segmented into autoimmune diseases, infectious diseases, cancer diagnosis, protein quantification, and others. The infectious diseases segment held the largest market share in 2022.
By end user, the North America ELISA diagnostics tests market is segmented into hospitals & diagnostic centers, pharmaceutical & biotechnology companies, veterinary hospitals & diagnostic laboratories, and others. The hospitals & diagnostic centers segment held the largest market share in 2022.
Based on country, the North America ELISA diagnostics tests market is segmented into the US, Canada, and Mexico. The US dominated the North America ELISA diagnostics tests market share in 2022.
Bio-Rad Laboratories Inc., Idexx Laboratories Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corp., Pictor Ltd., DiaSorin SpA, Elabscience Biotechnology Inc., and Bio-Techne Corp are some of the leading companies operating in the North America ELISA diagnostics tests market.